Lundbeck to acquire VC-backed Prexton
Lundbeck has agreed to acquire Prexton Therapeutics for 100 million euros and will later pay up to 805 million euros in development and sales milestones. Based in The Netherlands and in Switzerland, Prexton is a biopharmaceutical company. Prexton's investors include Forbion, Seroba Life Sciences, Sunstone Capital and Ysios Capital.
16 March 2018•4 mins read
